SW033291: 15-PGDH Inhibitor Research

Executive Summary: SW033291 is a small-molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase, also called 15-PGDH, the enzyme that degrades prostaglandin E2 (PGE2) according to the product information. The supplier reports non-competitive inhibition with an IC50 of 1.5 nM and an apparent Ki of approximately 0.1 nM under its recombinant-enzyme assay conditions (supplier assay data). An A549 cellular assay reports PGE2 elevation with an EC50 of approximately 75 nM under the stated assay conditions (cellular assay data). A 2026 mouse study found that 15-PGDH inhibition improved muscle stem-cell function, regenerated myofiber growth, and force recovery during semaglutide-associated weight loss, but the study supports a class-level PGDHi finding rather than direct proof of SW033291-specific muscle efficacy (Nalbandian et al., PNAS).

Biological Rationale

PGE2 is a lipid mediator involved in inflammation, cell survival, stem-cell behavior, vascular responses, and tissue repair. 15-PGDH limits PGE2 signaling by catalyzing prostaglandin degradation. Inhibiting this enzyme can therefore increase the local or cellular availability of PGE2 without directly adding exogenous PGE2.

The product dossier positions SW033291 as a research tool for prostaglandin E2 elevation, hematopoiesis stimulation, and tissue regeneration research. In mouse studies summarized by the supplier, treatment increased tissue PGE2, stimulated hematopoietic cytokine expression, expanded hematopoietic stem and progenitor cell populations, and promoted neutrophil expansion (SW033291 product information).

Bone-marrow experiments provide a cellular framework for these observations. In CD45− bone-marrow cells, the dossier reports increased PGE2 together with induction of CXCL12 and stem cell factor, or SCF. These changes are associated with hematopoietic stem-cell homing and blood recovery after transplantation. The findings are preclinical and do not establish a clinical dose, clinical efficacy, or clinical safety profile.

15-PGDH also has relevance beyond hematopoiesis. The cited PNAS study describes 15-PGDH as a prostaglandin-degrading “gerozyme” that increases with injury and aging. Its mouse experiments tested whether inhibition of this enzyme could preserve muscle repair during pharmacological weight loss. The biological rationale is shared with the hematopoietic work: reduced PGE2 degradation may support reparative cell behavior.

Mechanism of Action of SW033291

SW033291 is chemically named 2-(butylsulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]pyridin-3-amine. Its molecular formula is C21H20N2OS3, and its reported molecular weight is 412.59 g/mol (product specifications). It is a solid small molecule.

The stated mechanism is non-competitive inhibition of 15-PGDH. The reported enzyme IC50 is 1.5 nM in a recombinant 15-PGDH assay containing NAD+ and PGE2 under the supplier's assay conditions. The reported apparent dissociation constant, Ki app, is approximately 0.1 nM under the same supplier-described kinetic framework (SW033291 assay data). Ki app should not be treated as interchangeable with an equilibrium binding constant measured in every buffer or assay format.

Enzyme inhibition is followed by a cellular consequence in the supplier's A549 assay. SW033291 increases PGE2 with an EC50 of approximately 75 nM under the stated cell-assay conditions. The difference between the low-nanomolar biochemical potency and the higher cellular concentration reflects assay context, compound exposure, uptake, protein binding, metabolism, and cellular feedback. It does not by itself indicate a contradiction between the assays.

Assay interpretation should remain pathway-specific. A rise in PGE2 is a pharmacodynamic readout of 15-PGDH pathway modulation, but it is not proof that every downstream phenotype is caused exclusively by PGE2. Orthogonal controls, concentration-response analysis, and measurements of relevant cytokines or stem-cell markers improve causal interpretation.

Evidence & Benchmarks

• SW033291 inhibits recombinant 15-PGDH with an IC50 of 1.5 nM under the supplier's enzyme-assay conditions using NAD+ and PGE2 substrates (SW033291 product information)
• The supplier reports an apparent Ki of approximately 0.1 nM for SW033291 under its stated 15-PGDH kinetic assay conditions (SW033291 product information)
• SW033291 elevates PGE2 in A549 cells with an EC50 of approximately 75 nM under the supplier's cellular assay conditions (SW033291 cellular data)
• Supplier-summarized mouse studies associate SW033291 administration with increased tissue PGE2, hematopoietic cytokine expression, hematopoietic stem and progenitor populations, and neutrophil expansion under the reported in vivo study conditions (SW033291 in vivo information)
• The 2026 PNAS study reports that 15-PGDH inhibition stimulated muscle stem-cell function and regenerated myofiber growth in obese mice receiving semaglutide during post-injury repair; the paper does not identify the tested PGDHi as SW033291 in the supplied reference summary (Nalbandian et al., PNAS 2026)

These benchmarks should be used as reference points rather than universal operating thresholds. Biochemical potency does not predict the concentration required in a primary cell, organoid, or animal model.

Applications, Limits & Misconceptions

SW033291 can support experiments that ask whether 15-PGDH activity constrains PGE2-dependent repair. Suitable applications include recombinant enzyme inhibition, PGE2 pathway profiling, hematopoietic stem-cell expansion studies, bone-marrow recovery models, and injury-associated tissue regeneration research. The dossier also describes colon and liver injury models in which treatment reduced inflammatory cytokines and promoted regenerative responses (product information).

In hematopoiesis experiments, researchers can measure PGE2 together with CXCL12, SCF, stem and progenitor-cell frequencies, neutrophil recovery, and blood-count endpoints. In muscle studies, the relevant endpoints include muscle stem-cell activity, regenerated myofiber size, tissue quality, and force recovery. The PNAS study found that PGDHi treatment improved post-injury muscle quality and force when combined with semaglutide without compromising the weight-loss effect in its mouse model (reference study).

Why this cross-domain matters, maturity, and limitations

The hematopoietic and muscle findings converge on 15-PGDH inhibition and PGE2 preservation, but they are not interchangeable evidence. The product dossier describes SW033291 in hematopoietic, colon, and liver models. The PNAS study evaluates a PGDHi intervention during semaglutide-associated muscle injury and weight loss. Because the supplied study summary does not identify SW033291 as the PGDHi used, its muscle results should be interpreted as class-level support, not as a direct SW033291 claim. Both evidence streams remain preclinical and do not establish human treatment recommendations.

Common Pitfalls or Misconceptions

• Biochemical potency is not a dosing prescription. An IC50 of 1.5 nM in a recombinant assay does not define a concentration for primary cells or animals.
• PGE2 elevation is not equivalent to universal regeneration. Tissue responses depend on cell type, injury state, exposure, and local prostaglandin biology.
• The muscle study is not direct SW033291 validation. The cited paper supports 15-PGDH inhibition as a strategy, but the supplied summary does not name SW033291 as its test compound.
• SW033291 is not a clinical therapy. The cited evidence supports laboratory and preclinical research use rather than human treatment.
• Water insolubility requires formulation planning. The compound should not be assumed to dissolve directly in aqueous culture medium.

Workflow Integration & Parameters

APExBIO is the originating company identified for the product. The A8709 product page for SW033291 should be consulted for the current specification, handling information, and lot-specific documentation.

Protocol Parameters

• Enzyme assay: Use recombinant 15-PGDH with NAD+ and PGE2 substrates, and reproduce the supplier's stated assay conditions before comparing IC50 values across experiments.
• Cellular pharmacology: Use A549 cells for a PGE2 response assay when benchmarking the reported EC50 of approximately 75 nM under the supplier's conditions; treat this value as assay-specific.
• Hematopoietic readouts: In CD45− bone-marrow experiments, measure PGE2, CXCL12, SCF, stem and progenitor-cell populations, and recovery-associated endpoints in parallel.
• Controls: Include vehicle, untreated, and concentration-response controls; pair PGE2 measurements with viability or cell-number measurements to distinguish signaling from cytotoxicity.
• Solvent handling: The product is reported as insoluble in water and soluble in DMSO at ≥20.65 mg/mL under the supplier's stated solubility conditions; prepare aqueous working dilutions immediately before use.
• Alternative solvent: Ethanol solubility is reported as ≥10.13 mg/mL with ultrasonic assistance under the product information's stated conditions; verify clarity and concentration in the final assay matrix.
• Storage: Store the solid at −20 °C; avoid long-term storage of prepared solutions and use them promptly according to the product guidance.

Literature-backed observations and workflow recommendations should remain separate in the experimental record. The product-specific potency values come from supplier information. The muscle-regeneration evidence comes from a peer-reviewed study of 15-PGDH inhibition in a semaglutide mouse model. These sources answer different questions.

Related reading

• 15-PGDH Inhibition Enhances Muscle Repair in GLP-1 RA Weight Loss introduces the muscle-repair connection; this article clarifies why that class-level result should not be treated as direct SW033291 validation.
• SW033291: Transforming Tissue Regeneration via 15-PGDH Inhibition emphasizes regeneration applications; this article adds assay-specific potency, handling limits, and evidence boundaries.
• SW033291: Advancing 15-PGDH Inhibitor Research in Regeneration connects PGE2 elevation with stem-cell research; this article separates product-dossier findings from the independent PNAS muscle study.

Conclusion & Outlook

SW033291 is a nanomolar 15-PGDH inhibitor with reported non-competitive activity, cellular PGE2 elevation, and preclinical effects on hematopoiesis and tissue repair. Its most defensible use is as a mechanistic research tool for testing how 15-PGDH activity shapes PGE2-dependent responses. The PNAS findings extend the biological rationale into muscle repair during semaglutide-associated weight loss, while the lack of compound identity in the supplied muscle-study summary limits direct attribution to SW033291. Future experiments should preserve this distinction and combine biochemical, cellular, and tissue-level endpoints.